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ABSTRACT 1 
Mechanical loading represents a crucial factor in the regulation of skeletal homeostasis. Its 2 
reduction causes loss of bone mass, eventually leading to osteoporosis. In a previous global 3 
transcriptome analysis performed in mouse calvarial osteoblasts subjected to simulated 4 
microgravity, the most up-regulated gene compared to unit gravity condition was Lcn2, encoding 5 
the adipokine Lipocalin 2 (LCN2), whose function in bone metabolism is poorly known. To 6 
investigate the mechanoresponding properties of LCN2, we evaluated LCN2 levels in sera of 7 
healthy volunteers subjected to bed rest, and found a significant time-dependent increase of this 8 
adipokine compared to time 0. We then evaluated the in vivo LCN2 regulation in mice subjected to 9 
experimentally-induced mechanical unloading by i) tail suspension, ii) muscle paralysis by botulin 10 
toxin A (Botox) or iii) genetically-induced muscular dystrophy (MDX mice), and observed that 11 
Lcn2 expression was up-regulated in the long bones of all of them, while physical exercise 12 
counteracted this increase. Mechanistically, in primary osteoblasts transfected with LCN2-13 
expression-vector (OBs-Lcn2) we observed that Runx2 and its downstream genes Osterix and Alp 14 
were transcriptionally down-regulated, and ALP activity was less prominent versus empty-vector 15 
transduced osteoblasts (OBs-empty). OBs-Lcn2 also exhibited an increase of the Rankl/Opg ratio 16 
and IL-6 mRNA, suggesting that LCN2 could link osteoblast poor differentiation to enhanced 17 
osteoclast stimulation. In fact, incubation of purified mouse bone marrow mononuclear cells with 18 
conditioned media from OBs-Lcn2 cultures, or their co-culture with OBs-Lcn2, improved 19 
osteoclastogenesis compared to OBs-empty, while treatment with LCN2 had no effect. In 20 
conclusion, our data indicate that LCN2 is a novel osteoblast mechanoresponding gene and that its 21 
regulation could be central to the pathological response of the bone tissue to low mechanical forces. 22 
23 
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INTRODUCTION 1 
Lipocalin 2 (LCN2), also known as 24p3 and Neutrophil Gelatinase-Associated Lipocalin 2 
(NGAL)(1,2), is a 25-kD adipokine belonging to a large superfamily of proteins that bind and 3 
transport lipids and other hydrophobic molecules. Consistent with its expression in several cell 4 
types and organs, including neutrophils, adipocytes, macrophages, liver and kidney, LCN2 is 5 
implicated in diverse functions. For instance, it takes part in the host innate immune response 6 
through its bacteriostatic effect induced by the binding of bacterial enterobactin siderophores, which 7 
limits bacterial iron acquisition(3). Accordingly, LCN2 deficient mice are more sensitive to certain 8 
Gram-negative bacteria and die more readily of sepsis compared to wild type mice(4,5). 9 
 10 
Recently, it has been demonstrated a role of LCN2 also in the energy metabolism. Indeed, this 11 
protein is highly expressed in the adipose tissue and circulating LCN2 levels are increased in obese 12 
animals and in patients with type 2 diabetes(6,7). Moreover, serum concentrations of LCN2 are 13 
positively associated with waist circumference, percent of body fat, systolic blood  pressure, fasting 14 
glucose and  insulin concentrations, fasting triglycerides and markers of chronic inflammation(6). 15 
Serum LCN2 levels are also elevated in patients with coronary heart disease and are associated with 16 
atherosclerosis(8). Furthermore, the expression of LCN2 rises 1000-fold in humans and rodents in 17 
response to renal tubular injury, and it appears so rapidly in urine and serum that it is proposed to be 18 
an early biomarker of renal failure(9).  19 
 20 
So far, two LCN2 cell surface receptors have been identified. One receptor, called 24p3R (alluding 21 
to LCN2’s original name, 24p3), is a protein that originally was referred to as brain organic cation 22 
transporter, which is a membrane-associated protein with 12 predicted transmembrane helices(10). A 23 
second LCN2 receptor is the well-characterized multiprotein receptor megalin-cubulin(11), expressed 24 
by kidney proximal tubule cells, which are known target cells of LCN2(12).  25 
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Despite the several recognized functions accomplished by LCN2 in different tissues under 1 
physiologic and pathologic conditions, there are many questions still unsolved about the role of this 2 
molecule in the body. Since the function of LCN2 in bone homeostasis is barely known, we sought 3 
to investigate its involvement in this context based on a previous work in which we demonstrated 4 
that LCN2 could be a mechanoresponding gene that correlated with poor osteoblast activity(13). In 5 
fact, in a global transcriptome analysis of mouse calvarial osteoblasts grown for 5 days under 6 
modeled microgravity (0.08g and 0.008g) to simulate low mechanical loading, we evidenced 7 
modulation of transcripts involved in osteoblast differentiation, as well as changes in the expression 8 
of a set of genes not previously correlated with bone metabolism, among which the most up-9 
regulated gene was Lcn2(13).  10 
 11 
Based on this evidence, the aim of this study was to in-depth investigate the role of LCN2 in the 12 
response of bone to mechanical unloading in vivo and in vitro. We demonstrated that LCN2 is up-13 
regulated in human and animal models of reduced mechanical forces, and identified the cellular 14 
mechanisms underlying its effects on osteoblasts and osteoclasts. 15 
16 
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MATERIALS AND METHODS 1 
Materials 2 
DMEM (Dulbecco’s modified Minimum Essential Medium), FBS (Fetal Bovine Serum), penicillin, 3 
streptomycin and trypsin were from GIBCO (Uxbridge, UK). Sterile plastic ware was from Falcon 4 
Becton-Dickinson (Cowley, Oxford, UK) or Costar (Cambridge, MA, USA). Trizol reagent, 5 
primers and reagents for RT-PCR were from Invitrogen (Carlsbad, CA). The Brilliant® SYBR® 6 
Green QPCR master mix was from Stratagene (La Jolla, CA). Human recombinant (hr) Receptor 7 
Activator of Nuclear Factor κ-light-chain-enhancer of activated B cells transcription factor Ligand 8 
(RANKL) (#310-01) and  hrMacrophage-Colony Stimulating Factor (M-CSF) (#300-25) were from 9 
Peprotech (EC, London). Anti-megalin antibody (cat.#sc-16478) was from Santa Cruz 10 
Biotechnology, Inc. (Santa Cruz, CA); anti-LCN2 antibody (cat.# AF1857), mouse recombinant 11 
(mr) Lipocalin2 (cat.# 1857-LC-050) and  human ELISA kit for LCN2 (DLCN20) were purchased 12 
from R&D Systems Inc. (Minneapolis, MN).  All the other reagents were of the purest grade from 13 
Sigma Aldrich Co. (St. Louis, MO, USA). 14 
 15 
Ethics  16 
Approval for the study was obtained from the Ethical Committee of the “Aerztekammer 17 
Nordrhein”, Düsseldorf, Germany, and was conducted in accordance with the latest version of the 18 
Declaration of Helsinki. The study is registered on http://www.clinicaltrials.gov with the unique 19 
trial number: NCT01183299 and registration date: 08/13/2010.  20 
 21 
Protocol for the human study 22 
Primary focus of this bed rest study was to test if low-grade metabolic acidosis induced by high 23 
NaCl intake exacerbates bone resorption during immobilisation. For this reason, a 14-day head-24 
down tilt bed rest (HDBR) study, including 8 male test subjects [mean age: 26.3 ± 3.5 years; body 25 
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weight (BW) 78.0 ± 4.3 kg] was conducted in the metabolic ward of the German Aerospace Center. 1 
Immobilization was accomplished with 6 degree HDBR, a valid ground-based model to simulate 2 
microgravity-induced bone loss(14). During the bed rest period  the subjects received in a cross-over 3 
design either a high (7.7 mEq /kg BW per day) or a low (0.7 mEq /kg BW per day) NaCl diet. The 4 
two parts of the study were performed separately with a 6-month washout period in between. Study 5 
design and primary outcome are described more detailed in Frings-Meuthen et al(14). For the 6 
assessment of serum LCN2 levels in the present study, we took advantage of unutilized study 7 
samples. 8 
 9 
Blood sampling and analysis 10 
Blood samples were drawn on day 0 just before confinement to bed and during bed rest on days 4, 11 
6, 8, 11 and 15. Blood samples were obtained by venipuncture from a forearm vein and collected 12 
into 5-ml serum separator tubes. After centrifugation, serum samples were aliquoted into 1ml 13 
cryotubes and kept frozen at −80 °C until use. LCN2 concentration was measured using a 14 
commercially available ELISA kit according to the manufacturer's recommendations.  15 
 16 
Animals 17 
Procedures involving animals care were conducted in conformity with national and international 18 
laws and policies (EEC Council Directive 86/609, OJ L 358, 1, Dec. 12, 1987; Italian Legislative 19 
Decree 116/92, Gazzetta Ufficiale della Repubblica Italiana n. 40, Feb. 18, 1992; NIH guide for the 20 
Care and Use of Laboratory Animals, NIH Publication No. 85-23, 1985), and were approved by the 21 
Institutional Review Board of the University of L’Aquila. At the end of the experiments, mice were 22 
sacrificed by CO2 inhalation.  All experiments were performed in female mice. Key experiments 23 
repeated in male mice showed similar results (not shown). 24 
 25 
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Hindlimb suspension 1 
Hindlimb suspension was obtained according to Sakata et al.(15) on 8 week-old C57BL/6 mice. A 2 
strip of elastic tape forming half a circle at the center of the tail was applied to the ventral surface of 3 
the tail. A swivel attached to the half circle of tape was fixed to an overhead wire, the height of 4 
which was adjusted to maintain the mice suspended at an approximately 30° angle. The swivel 5 
apparatus allowed animals to readily access to food and water and to move freely into the cage 6 
using their forelimbs. After 21 days of suspension mice were sacrificed by CO2 inhalation, 7 
hindlimbs were removed and cleaned from soft tissues, then they were frozen in dry ice and 8 
subjected to RNA extraction. An equal number of mice was maintained under normal cage 9 
conditions for 21 days as control.  10 
 11 
In vivo treatment with botulin toxin A (Botox) 12 
Eight week-old C57BL/6 mice were subjected to Botox injection according to Warner et al.(16). 13 
Briefly, mice were anesthetized, then the left and the right hindlimbs of each mice were injected 14 
with saline solution (20 μl) and with Botox (2.0 unit/100gr), respectively, into the right quadriceps 15 
and the posterior compartment of the right calf (targeting gastrocnemius, plantaris, and soleus). The 16 
behavioral response of each mouse was quantified on days 1, 3, 7 and weekly thereafter using 17 
whole body weight measurement and assessment of gait disability. After 21 days mice were 18 
sacrificed, then the hindlimbs were removed, femurs and tibias were cleaned free of soft tissues and 19 
frozen in dry ice or fixed in 4% buffered paraformaldehyde for RNA extraction and morphometric 20 
analysis of bone parameters, respectively.  21 
 22 
MDX mice 23 
Eight week-old MDX (X chromosome-linked muscular dystrophy) homozygous mice 24 
(CB6F1/C57BL6 background) carrying a spontaneous single-base mutation on exon 23 of the 25 
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dystrophin gene(17,18) were used for analysis of the bone phenotype and for mRNA expression of 1 
LCN2 in tibias. Age-matched normal mice of the same background were employed as controls. 2 
Mice were euthanized by CO2 inhalation, and hindlimb bones were excised, cleaned of soft tissues, 3 
frozen in dry ice and processed for RNA extraction.  4 
 5 
Treadmill exercise 6 
Wild-type (WT) and MDX mice were enforced to run on a mobile platform at a speed of 9 m/min 7 
for 30 min, twice a week for 3 weeks. Since mice carried muscular dystrophy, to avoid excessive 8 
stress due to increasing running time, physical exercise was not progressive. 9 
 10 
Forced swimming test 11 
WT mice subjected to hindlimb suspension were forced to swim in a 250 L water-filled tank (water 12 
depth=20 cm), with water temperature kept at 31°C. This test lasted 5 min and was repeated 3 13 
times/day for 3 days/week during the entire period of unloading (3 weeks)(19). Control mice were 14 
left for the same time of swimming test under unloading conditions. 15 
 16 
Micro Computed Tomography (μCT) analysis  17 
Tibias were mounted and acquired in a SkyScan 1174 with a voxel size of 6 μm (X-ray voltage 50 18 
kV). Image reconstruction was carried out employing a modified Feldkamp algorithm using the 19 
Skyscan Nrecon software. Beam hardening correction and Fourier transform based ring artifact 20 
reduction were applied to the reconstructed images. ThreeD and 2D morphometric parameters were 21 
calculated for the trabecular bone of selected regions of interest, 150 slides 400 μm from the growth 22 
plate. Threshold values were applied for segmenting trabecular bone corresponding to bone mineral 23 
density values of 0.6/cm3 calcium hydroxyapatite. ThreeD parameters were based on analysis of a 24 
Marching Cubes type model with a rendered surface(20). Calculation of 2D areas and perimeters was 25 
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based on the Pratt algorithm. Bone structural variables and nomenclature were those suggested in 1 
Bouxsein et al.(21).  2 
 3 
Bone histomorphometry 4 
Tibias fixed in 4% paraformaldehyde were dehydrated in acetone and processed for glycol–5 
methacrylate embedding without decalcification. Histomorphometric measurements were carried 6 
out on 5 µm–thick sections with an interactive image analysis system (IAS 2000; Delta Sistemi, 7 
Rome, Italy)(22) and with the suggested nomenclature(23). Osteoclast surface/bone surface (%) was 8 
evaluated  after histochemically staining the sections for TRAcP activity. Osteoblast surface/bone 9 
surface (%) was evaluated after staining the sections with methylene blue/azure II. 10 
 11 
Bone biomechanical properties  12 
Explanted femurs were cleaned out of soft tissues and stored at -80°C. They were then thawed in 13 
ice and soaked in ice-cold PBS. The analysis was performed on the distal portion of the femur using 14 
the Reference Point Indentation (Biodent Hfc, Active Life Scientific, Santa Barbara, CA). Samples 15 
were tested using the test probe BP2 and the following parameters: 10 indentation cycles at 2 Hz to 16 
a force of 4 N. Bones were maintained in an hydrated state throughout the test. Total indentation 17 
distance and total energy dissipation were calculated for each test. Five tests from each animal were 18 
averaged to produce a single value for each variable. 19 
 20 
Calvarial osteoblast cultures 21 
Calvariae from 7 day-old CD1 mice were removed, cleaned free of soft tissues and digested three 22 
times with 1 mg/ml Clostridium histolyticum type IV collagenase and 0.25% trypsin, for 20 min at 23 
37°C with gentle agitation. Cells from the second and third digestions were plated and grown in 24 
standard conditions, in DMEM plus 10% FBS. At confluence, cells were trypsinized by standard 25 
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procedures and plated according to the experimental protocol. These cells expressed the osteoblast 1 
markers ALP, Runx-2, parathyroid hormone (PTH)/PTH related peptide receptor, type I collagen, 2 
and osteocalcin. 3 
 4 
Alkaline Phosphatase (ALP) activity assay 5 
Primary mouse osteoblasts were fixed in 4% paraformaldehyde for 15 min, then washed with PBS. 6 
ALP activity was evaluated histochemically using the Sigma-Aldrich kit n. 85, according to the 7 
manufacturer’s instruction. Quantitative analysis was performed by scanning densitometry using the 8 
Molecular Analyst software for the model 670 scanning densitometer (Bio-Rad Laboratories) to 9 
obtain arbitrary density units. 10 
 11 
Amaxa nucleofector transfection  12 
One x106 primary mouse osteoblasts were nucleofected with 2 μg of empty- or LCN2-carrying 13 
pCMV-3TAG8 vectors, using the Amaxa Mouse Neuron Nucleofector kit (Lonza Cat. VPG-1001) 14 
and the program X-010 of the nucleofector device. After 48 hours from nucleofection, osteoblasts 15 
were employed for the experiments. 16 
 17 
Osteoclast primary cultures 18 
Bone marrow flushed out from the bone cavity of the long bones of 7 day-old CD1 mice was 19 
diluted 1:1 in Hank’s balanced salt solution, layered over Histopaque 1077 solution and centrifuged 20 
at 400 g for 30 minutes. Cells were washed twice with Hank’s solution, re-suspended in DMEM 21 
and plated in culture dishes at a density of 106 cells/cm2. After 3 hours, cell cultures were rinsed to 22 
remove non-adherent cells and maintained for 7 days in the same medium supplemented with 50 23 
ng/ml rhM-CSF and suboptimal concentrations of  rhRANKL (30 ng/ml), plus 100 ng/ml rmLCN2 24 
or undiluted conditioned media from osteoblasts overexpressing LCN2 or transfected with an empty 25 
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vector as control. 1 
 2 
Osteoblast-osteoclast co-cultures 3 
Primary mouse osteoblasts, transfected by the AMAXA method with the LCN2 vector or with an 4 
empty vector, were plated in 48 well plates. When cells reached 30% confluence, purified mouse 5 
bone marrow mononuclear cells, obtained by the above described protocol, were added to the 6 
osteoblast cultures at a density of 106 cells/ml. After 7 days of co-culture, osteoclasts were detected 7 
by Tartrate-Resistant Acid Phosphatase (TRAcP) histochemical staining. 8 
 9 
TRAcP activity assay  10 
Cells were fixed in 4% paraformaldehyde for 15 min, then extensively washed with the same 11 
buffer. TRAcP activity was detected histochemically, using the Sigma-Aldrich kit # 386, according 12 
to the manufacturer’s instruction. 13 
 14 
Immunoisthochemistry 15 
Tibias were cleaned  free of soft tissues and fixed  with 4%  paraformaldehyde for 48 hours,  then 16 
decalcified in Osteodec for further 48 hours and embedded in paraffin to obtain 5µm thick sections. 17 
Sections were then deparaffinized, incubated  with 0.07 M citrate buffer (pH 6) for 15 minutes at 98 18 
°C for antigen retrieval, treated with 3% H2O2, and incubated overnight at 4 °C with the anti-Lcn2 19 
mouse monoclonal antibody. The staining signal was revealed using the Dako LSAB System-HRP 20 
(cat# K0679, Dako North America, Inc., Carpinteria, CA, USA) following the manufacturer’s 21 
instructions. Negative controls (omitting the primary antibody) were performed in parallel. 22 
 23 
 24 
 25 
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Immunofluorescence 1 
Mouse primary osteoblasts were fixed with 4% paraformaldehyde and incubated for 1 h at room 2 
temperature with specific primary antibodies followed by FITC- or TRITC-conjugated secondary 3 
antibody. To detect nuclei, cells were stained with DAPI. Cells were then observed at room 4 
temperature by conventional epifluorescence (Axioplan; Carl Zeiss, Inc.) confocal (FluoView IX81 5 
FVBF; Olympus) microscope. For fluorescence microscopy, we used 2.5× NA 0.075, 10× NA 0.30, 6 
20× NA 0.5, and 40× NA 0.75 Plan-Neofluar objective lenses. Images were captured with a camera 7 
(AxioCam MRC5; Carl Zeiss, Inc.) using the AxioVs 40 version 4.7.1.0 software (Carl Zeiss, Inc.). 8 
For confocal microscopy, we used 10× NA 0.30 and 40× NA 0.85 UPlan-Apochromat or 60× NA 9 
1.4 oil Plan-Apochromat objective lenses. Images were captured using FluoView 500 software 10 
(Olympus). 11 
 12 
Human Embryonic Kidney (HEK)293 cells 13 
The HEK293 cell line was obtained from the American Tissue Culture Collection (ATCC, 14 
Rockville, MD), and grown in DMEM supplemented with 10% FBS, 100 IU/ml penicillin, 100 15 
µg/ml streptomycin, and 2 mM L-glutamine. Cells were grown in a 5% CO2 humidified atmosphere 16 
at 37°C. 17 
 18 
To overexpress LCN2, HEK293 cells were transiently transfected with the pCMV-3TAG8 19 
expression vector containing LCN2, using the lipofectamine and PLUS reagent. Control 20 
transfectants were obtained by transfecting HEK293 cells with an empty pCMV-3TAG8. 21 
 22 
Semi quantitative and comparative real time RT-PCR 23 
Total RNA was extracted from mouse whole femurs or from osteoblasts using the Trizol® 24 
14 
 
procedure. RNA (1 μg) was reverse transcribed in cDNA using M-MLV reverse transcriptase and 1 
the equivalent of 0.1 μg was employed for the real time PCR reactions using the Brilliant® SYBR® 2 
Green QPCR master mix or for semiquantitative PCR. PCR conditions and primer pairs are listed in 3 
Table 1. Results, expressed as fold increase for real time RT-PCR, or shown by electrophoresis of 4 
PCR products in a 2% agarose gel plus ethidium bromide for conventional RT-PCR, were 5 
normalized versus the housekeeping gene Gapdh.  6 
 7 
Statistics 8 
Results are expressed as the mean ± SD of at least three independent experiments, 8 human subjects 9 
and at least 3 mice/group. Statistical analyses were performed by the Student's t test, the linear 10 
regression test or the non-parametric Mann–Whitney Runk Sum Test, according to the type of data 11 
sets. Statistical method is indicated in the figure legends. A p value <0.05 was conventionally 12 
considered statistically significant. 13 
14 
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RESULTS 1 
LCN2 expression in sera of patients subjected to prolonged bed rest 2 
In our previous study we demonstrated that Lcn2 is a mechanoresponding gene, up-regulated in 3 
mouse primary osteoblasts by mechanical unloading simulated in the NASA-developed rotating 4 
wall vessel bioreactor by reducing the gravitational forces(13). Based on these data, we evaluated 5 
LCN2 in healthy volunteers, subjected to HDBR, an analogue model used to mimic microgravity-6 
induced bone and muscle loss. This trial was originally designed to investigate the association 7 
between high NaCl intake, concomitant with a low-grade metabolic acidosis, and exacerbated bone 8 
resorption and protein wasting(14). We took advantage of unutilized study samples and found that 9 
the serum LCN2 levels were higher after HDBR if compared to basal levels (time 0) (Fig. 1), 10 
revealing direct correlation between LCN2 levels and time of HDBR. Changes were not associated 11 
to sodium intake as suggested by the lack of statistical significance between the low (Fig. 1, black 12 
symbols) and the high (Fig. 1, open symbols) sodium intake groups at each time point. Induction of 13 
LCN2 was progressive and achieved statistical significance after 12 days of HDBR (Fig. 1). In 14 
agreement with our previous in vitro findings, that demonstrated an increase of LCN2 in primary 15 
osteoblasts picking after 5 days of unloading(13), we can conclude that LCN2 induction is not an 16 
early event as it requires days of stimulation by decreased mechanical forces.  17 
 18 
LCN2 expression in the bones of animal models subjected to unloading condition 19 
The evidence in humans, together with the in vitro results previously obtained in isolated murine 20 
osteoblasts(13), prompted us to further characterize the relationship between Lcn2 expression and the 21 
response of bone to reduced mechanical forces in animal models. We first employed the tail 22 
suspension of mice as a model of hindlimb unloading(15) and found that the mRNA expression of 23 
Lcn2 significantly increased in the bones of the suspended hindlimbs with respect to those of the 24 
hindlimbs of mice maintained under normal conditions, employed as controls (Fig. 2A). 25 
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Noteworthy, this increase was antagonized by physical exercise through the forced swimming test 1 
(Fig. 2A).  2 
 3 
To identify the cell lineage producing more LCN2 in tail suspended mice, we performed a FACS 4 
analysis of bone marrow cells flushed out from femurs. We found that the CD45- subpopulation, 5 
known to represent the bone marrow stromal cells and to include the osteoblast lineage, was the 6 
only one responding to the unloading conditions by increasing its LCN2 expression. This increase 7 
was again antagonized by the physical exercise (Fig. 2B).  8 
 9 
Next we asked whether the biomechanical properties of the bones of these mice, known to be 10 
impaired by unloading (Fig. 2C,D), correlated with the Lcn2 modulation. Indeed, the regression test 11 
showed a direct correlation between Lcn2 transcriptional expression and the total indentation 12 
distance (Fig. 2E), a parameter that increases when the bone quality is compromised. 13 
 14 
We have previously reported that dystrophic homozygous MDX mice(17) are characterized by an 15 
osteopenic phenotype(18). In these mice we analyzed the Lcn2 mRNA expression in bone and, 16 
consistent with the results of hindlimb suspension, we observed that it was significantly increased 17 
with respect to the WT littermates (Fig. 2F). This increase was prevented subjecting the MDX mice 18 
to physical exercise by treadmill running (Fig. 2F). 19 
 20 
We next created an additional model of mechanical unloading injecting Botox in both quadriceps 21 
and calf muscles of the right hindlimbs of 5 week-old mice. This procedure induced a transient 22 
paralysis causing a dramatic alteration of muscle organization, as demonstrated by 23 
hematoxylin/eosin staining of muscle sections (Fig. 3A). As expected(16), this mechanical 24 
impairment induced a reduction of bone volume/total tissue volume (Fig. 3B) and trabecular 25 
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number (Figure 3C), no modulation of trabecular thickness (Fig. 3D) and an increase of trabecular 1 
separation (Fig. 3E). Histomorphometric analysis revealed an increase of osteoclast surface (Fig. 2 
3F), together with a decrease of osteoblast surface (Fig. 3G) over bone surface and a trend of 3 
increase of bone marrow adiposity (Fig. 3H,I). Again, under this loading constrain we observed a 4 
significant increase of LCN2 both at protein (Fig. 4A) and transcriptional (Fig. 4B) level. 5 
Consistently, serum level of LCN2 was time-dependently increased in Botox-treated mice 6 
compared to control mice (Fig. 4C). Biomechanical tests confirmed impaired mechanical properties  7 
induced by unloading (Fig. 4D,E), while regression tests evidenced that Lcn2 mRNA level had a 8 
direct correlation with the reduction of mechanical strength (Fig. 4F) and an inverse correlation 9 
with the bone volume/total tissue volume (Fig. 4G). 10 
 11 
To address whether high Lcn2 levels were involved in bone mass loss also independently of 12 
mechanical unloading, we evaluated Lcn2 expression in ovariectomized (OVX) mice and observed 13 
that, in this circumstance, Lcn2 expression was significantly reduced both at transcriptional and 14 
protein level compared to sham operated mice (Supplementary Fig. 1A,B). This result suggests that 15 
LCN2 overexpression represents a specific response of bone to mechanical release. 16 
 17 
Role of LCN2 in osteoblast activity 18 
To dissect the role of LCN2 in osteoblast metabolism, mouse primary osteoblasts were transfected 19 
with Lcn2-expression-vector (OBs-LCN2) or with control empty vector (OBs-empty). Successful 20 
overexpression of LCN2 was confirmed at mRNA (Fig. 5A) and protein (Fig. 5B) levels by real 21 
time RT-PCR and ELISA assays, respectively. Interestingly, OBs-LCN2 exhibited a less 22 
differentiated phenotype, as indicated by a lower transcriptional expression of Alp (Fig. 5C), Runx2 23 
(Fig. 5D) and Osterix (Fig. 5E) genes, compared to OBs-empty. Consistently, histochemical 24 
evaluation of ALP evidenced a lower activity in OBs-LCN2 versus OBs-empty (Fig. 5F). Primary 25 
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osteoblasts transfected with Runx2 expression vector (Supplementary Fig. 2A) showed no change of 1 
Lcn2 transcriptional level (Supplementary Fig. 2B), implying that Lcn2 is likely to represent a 2 
primary osteoblast gene not subjected to Runx2 regulation. Finally, in OBs-LCN2 we observed an 3 
increase of phosphorylated ERK, suggesting the involvement of the MAPK pathway in the LCN2 4 
signaling (Fig.5G). Accordingly, osteoblasts expressed both LCN2 receptors, 24p3R and megalin 5 
(Fig 5H,I) which, however, were not modulated during osteoblast differentiation as demonstrated 6 
by the lack of correlation with the osteoblast differentiating genes Alp and Runx 2, and with Lcn2 7 
itself (Supplementary Fig. 2C). These results support a dominant role of LCN2 in causing the poor 8 
osteoblast differentiation observed in our previous study performed under simulated microgravity(24) 9 
and underscore the involvement of a receptor-mediated mechanism associated to the ERK pathway. 10 
 11 
Role of LCN2 on osteoclast activity 12 
Since osteoblasts are the main players in the regulation of osteoclast formation and function, we 13 
asked whether LCN2 overexpression could interfere with the paracrine production of osteoclast 14 
regulating cytokines. In line with this hypothesis, we observed that OBs-LCN2 produced a 15 
significantly higher amount of the osteoclastogenic cytokines Receptor Activator of Nuclear Factor 16 
Kappa B Ligand (RankL) (Figure 6A) and InterLeukin 6 (IL6) (Fig. 6B), and a lower expression of 17 
the RANKL decoy receptor Osteoprotegerin (Opg) (Fig. 6C), thus leading to a significant increase 18 
of the RankL/Opg ratio (Fig. 6D).  19 
 20 
These results prompted us to investigate whether LCN2 could indirectly affect osteoclastogenesis 21 
by treating mouse bone marrow mononuclear cells with conditioned media collected from OBs-22 
LCN2 or OBs-empty. This experiment evidenced a significant increase of osteoclast number in the 23 
presence of conditioned medium from OBs-LCN2 (Fig. 6E). Similar results were observed in 24 
purified bone marrow mononuclear cells co-cultured with OBs-LCN2 relative to OBs-empty (Fig. 25 
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6F). This osteoclastogenic effect was not due to the LCN2 itself because the treatment of pre-1 
osteoclast cultures with rmLCN2 failed to increase osteoclastogenesis over control (Fig. 6G). 2 
 3 
In order to address whether LCN2 overexpression could induce similar changes in a cell type not 4 
correlated with bone, we transfected the human epithelial cell line HEK293 with empty- or LCN2-5 
carrying vectors (Fig. 7A). Under this condition, increased LCN2 also induced RankL mRNA 6 
expression (Fig. 7B), with albeit no effects on Opg expression (Fig. 7C). Nevertheless, the RankL 7 
change led to a significant increase of the RankL/Opg ratio (Fig. 7D). In contrast, we did not 8 
observe any regulation of IL-6 mRNA level (Fig.7E).  9 
 10 
Consistent with the induction of RankL, enhanced osteoclast formation was demonstrated in 11 
experiments in which purified bone marrow mononuclear cells were cultured in the presence of 12 
conditioned medium from HEK293 cells transfected with control or LCN2 vector (Figure 7F). This 13 
effect was blunted by treatment with OPG (Figure 7G), confirming that it was due to the increased 14 
RANKL concentration in the conditioned medium of LCN2 overexpressing cells.  15 
16 
20 
 
DISCUSSION 1 
LCN2 is a very versatile molecule that plays different roles in several cell types and conditions. It 2 
has recently been the subject of a great interest as an early biomarker not only in renal injury but 3 
also in several other conditions, including cancer, anemia, pregnancy and cardiovascular diseases(25-4 
28)
. The multifaceted roles of LCN2 are well evident in tumor cells, where the proposed functions 5 
range from inhibiting apoptosis(29), invasion and angiogenesis(30), to increasing proliferation and 6 
metastasis(31,32). Ectopic expression of LCN2 also promotes BCR-ABL-induced chronic 7 
myelogenous leukemia in murine models(33).  Moreover, it forms a complex with the proteolytic 8 
enzyme matrix metalloprotease-9 (MMP-9), thus preventing its degradation(34).  9 
 10 
Despite these many different functions, the role of LCN2 in bone metabolism is still unclear and 11 
only recently some researches are starting to elucidate it. Costa and colleagues showed an increased 12 
expression of SDF-1 in transgenic mice overexpressing LCN2 specifically in osteoblasts under the 13 
control of a type I collagen promoter, that correlated with an increased number of CD34+/CXCR4+ 14 
(SDF-1 receptor) cells(35). These mice also exhibited growth plate defect, reduced bone mass, 15 
delayed osteoblast differentiation and enhanced osteoclast activity, thus supporting our 16 
observations(36). In fact, in our hands, LCN2 appears to have a crucial role especially in conditions 17 
associated to a decrease of mechanical forces. Our previous work(13) demonstrated that osteoblasts 18 
progressively up-regulate LCN2 expression in a manner proportional to the reduction of 19 
gravitational force intensity. Interestingly, in the present study, we demonstrated a direct correlation 20 
between LCN2 serum levels and the mechanical unloading mimicked in human subjects by HDBR 21 
condition. These results were also confirmed in vivo in the long bones of various animal models of 22 
mechanical unloading, strongly indicating a causative role of LCN2 in inducing bone loss. 23 
Noteworthy, Miravète et al.(37) suggested a role of LCN2 in urinary fluid shear stress-induced 24 
alterations observed in early phases of most kidney diseases, confirming the mechanoresponding 25 
21 
 
properties of this gene also in another context. Interestingly, our data indicate that increased Lcn2 1 
expression is specifically associated to unloading-induced bone loss. In fact, contrariwise, in 2 
ovariectomized (OVX) mice, which typically reproduce a condition of bone loss independent of 3 
mechanical forces, we found a significant reduction of LCN2 compared to sham operated mice. 4 
These data suggest that LCN2 could play an alternative role in postmenopausal osteoporosis, 5 
underscoring the need of further work to deeply understand its complex involvement in the context 6 
of bone metabolism.  7 
  8 
Mechanistically, in vivo CD45- cells, known to belong to the stromal cellular component of the 9 
bone marrow that also includes the osteoblast lineage, were the major sources of LCN2 in 10 
unloading conditions. Furthermore, increased LCN2 levels matched with an inhibition of osteoblast 11 
differentiation, as demonstrated by our in vitro study, where the overexpression of LCN2 alone in 12 
osteoblasts sufficed to inhibit their differentiation. In fact, crucial osteoblast genes such as Runx2, 13 
Osterix and Alp, which were previously noted to be down-regulated under reduced mechanical 14 
forces in vitro(13), were blunted in osteoblasts overexpressing LCN2. Our results also suggest that 15 
LCN2 works upstream of the typical osteoblast master protein, Runx2, representing a novel primary 16 
osteoblast differentiation regulatory pathway.  17 
 18 
Interestingly, LCN2 also appears to contribute to the osteoblast-osteoclast coupling. In fact, 19 
overexpression of LCN2 in osteoblasts increased their ability to stimulate osteoclastogenesis 20 
through the induction of the pro-osteoclastogenic factors, RANKL and IL-6, and the inhibition of 21 
the anti-osteoclastogenic factor, OPG. The induction of RANKL by LCN2 was observed also in a 22 
bone-unrelated cell line (HEK293). Consistently, HEK293 cell conditioned medium had pro-23 
osteoclastogenic properties fully blocked by treatment with the RANKL-decoy receptor, OPG. In 24 
contrast, LCN2 did not exhibit pro-osteoclastogenic properties itself, suggesting a dominant role 25 
22 
 
only in osteoblasts, which reliably expressed both LCN2 receptors, megalin and 24P3R, and 1 
responded to LCN2 overexpression through the ERK pathway. 2 
 3 
In conclusion, we believe that LCN2 is an important osteoblast mechanoresponding gene with a 4 
role in bone metabolism, that could be involved in the onset of osteoporosis induced by mechanical 5 
failures due for instance to disuse, bed rest, muscle impairment or aging, decreasing osteoblast 6 
differentiation and increasing osteoblast-induced osteoclastogenesis. These results open new 7 
perspective in the understanding of the molecular mechanisms governing bone metabolism under 8 
stimulation by mechanical forces in physiologic and pathologic conditions, and establish a track for 9 
diagnostic and therapeutic developments also in humans. 10 
 11 
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Table 1: Primer pairs employed for comparative real time and semiquantitative RT-PCR.  1 
Gene Primers 
 Forward Reverse 
GAPDH 5’-TGGCAAAGTGGAGATTGTTGC -3’ 5’-AAGATGGTGATGGGCTTCCCG -3’ 
Lcn 2 5’-CCAGTTCGCCATGGTATTTT-3’ 5’-CACACTCACCACCCATTCAG-3’ 
Alp 5’-CCAGCAGGTTTCTCTCTTGG-3’ 5’-CTGGGAGTCTCATCCTGAGC-3’ 
Runx2 5’-AACCCACGGCCCTCCCTGAACTCT-3’ 5’-ACTGGCGGGGTGTAGGTAAAGGTG-3’ 
Osterix 5’-TGCTTCCCAATCCTATTTGC-3’ 5’-AGAATCCCTTTCCCTCTCCA-3’ 
IL-6 5’-GAGGATACCACTCCCAACAGACC-3’ 5’-AAGTGCATCATCGTTGTTCATACA-3’ 
RankL 5’-CCAAGATCTCTAACATGACG-3’ 5’-CACCATCAGCTGAAGATAGT-3’ 
Opg 5’-AAAGCACCCTGTAGAAAACA-3’ 5’-CCGTTTTATCCTCTCTACACTC -3’ 
PCR conditions were 94°C 30 sec, 60°C 30 sec, 72°C 30 sec, replicated for 40 cycles for real time RT-PCR 2 
and 27 cycles for semiquantitative RT-PCR. 3 
4 
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FIGURE LEGENDS 1 
Figure 1: LCN2 expression in sera of patients subjected to prolonged head-down tilt bed rest 2 
(HDBR). (A) ELISA assay for human LCN2 performed in sera of 8 healthy volunteers subjected to 3 
HDBR (15 days). Sera were collected just before the HDBR (day 0) and during the HDBR (days 1, 4 
3, 6, 8, 11, 15). Open squares: 500 mmoles NaCl/day, black squares: 50 mmoles NaCl/day. 5 
*P=0.003 and **P=0.001 versus day 0; differences between 500 mmoles NaCl/day and 50 mmoles 6 
NaCl/day are statistically not significant, with P>0.21 (paired t-test).  7 
 8 
Figure 2: Effect of in vivo mechanical unloading on LCN2 expression. Eight week-old mice 9 
were maintained in Normal Loading Conditions (NLC) or were subjected to HindLimb Suspension 10 
(HLS) for 21 days. A group of them was subjected to physical Exercise (HLS+E) (forced 11 
swimming test) during the experiment of unloading, as described in Materials and Methods.  (A) 12 
Transcriptional evaluation of Lcn2 expression in the hindlimb bones by comparative real time RT-13 
PCR. (B) Evaluation by FACS analysis of the percent of CD45-/LCN2+ cells in the bone marrow. 14 
(C) Dissipated Energy (DE, µJ) and (D) Total Indentation Distance (TID, µm) in distal femurs. (E) 15 
Linear regression test showing a direct correlation between Lcn2 mRNA and distal femoral TID. 16 
Data are the mean ± SD. *P< 0.038 and **P = 0.016 versus NLC (Non-parametric Mann-Whitney 17 
Runk Sum Test). (F) Transcriptional expression of Lcn2 by comparative real time RT-PCR in eight 18 
week-old wild type (WT) and MDX (X chromosome-linked muscular dystrophy) mice, the latter 19 
maintained under sedentary conditions or subjected to physical Exercise (MDX+E) (treadmill 20 
running). ***P= 0.001 versus WT and #P=0.002 versus MDX (Non-parametric Mann-Whitney Runk 21 
Sum Test). 22 
 23 
Figure 3: Effect of transient paralysis on bone phenotype. Eight week-old mice were injected 24 
with saline solution (vehicle) or with Botulin toxin A (Botox, 20 μl of 2.0 unit/100gr), into the right 25 
30 
 
quadriceps and the posterior compartment of the right calf (targeting gastrocnemius, plantaris, and 1 
soleus) 4 mm proximal to the patellar tendon of the left or the right hindlimbs, respectively. (A) 2 
Hematoxylin/eosin staining of muscle sections. (B-E) μCT analysis of proximal tibia spongiosa to 3 
quantify trabecular (B) bone volume/total tissue volume (BV/TV %), (C) number (TbN), (D) 4 
thickness (TbTh) and (E) separation (TbSp). (F,G) Histomorphometric analysis of proximal tibia to 5 
quantify (F) osteoclast surface/bone surface (OcS/BS) and (G) osteoblast surface/bone surface 6 
(ObS/BS). (H) Representative picture of femur sections stained with hematoxylin/eosin (B=bone, 7 
BM=bone marrow) and (I) quantification of the adipocyte number. *P<0.03, **P= 0.012 versus  8 
vehicle (unpaired t-test). In (D) and (I) data are statistically not significant, with P>0.1 and P=0.17 9 
versus vehicle, respectively. 10 
 11 
Figure 4: Effect of transient paralysis on LCN2 transcriptional and protein expression. Right 12 
quadriceps of 8 week-old mice injected with saline solution (vehicle) or with Botulin toxin A 13 
(Botox, 20 μl of 2.0 unit/100gr). (A) Immunocytochemistry for LCN2 detection in tibia sections 14 
(B=bone, BM=bone marrow). (B) Transcriptional expression of Lcn2 by comparative real time RT-15 
PCR. (C) Linear regression test showing a direct correlation between serum LCN2 levels and the 16 
duration of unloading. (D) Distal femur Dissipated Energy (DE, µJ) and (E) Total Indentation 17 
Distance (TID, µm). (F,G) Linear regression test showing (F) a direct correlation between Lcn2 18 
mRNA and the Total Indentation Distance, and (G) an inverse correlation between Lcn2 mRNA 19 
and trabecular bone volume/total tissue volume (BV/TV).**P<0.04 versus vehicle (Non-parametric 20 
Mann-Whitney Runk Sum Test). 21 
 22 
Figure 5: Effect of LCN2 overexpression on osteoblast differentiation. (A-F) AMAXA 23 
nucleofection of primary osteoblasts with LCN2 (OBs-LCN2) or with an empty vector as control 24 
(OBs-empty). (A) mRNA and (B) protein expressions of LCN2 performed by comparative real time 25 
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RT-PCR and ELISA assays, respectively. (C-E) Transcriptional expression of (C) Alp, (D) Runx2 1 
and (E) Osterix by comparative real time RT-PCR. (F) Quantification (graph) of ALP activity 2 
evaluated by histochemical assay (inset). (G) Western blot analysis of phosphorylated ERK (pERK) 3 
and total ERK. (H) mRNA and (I) protein expression of the LCN2 receptors, megalin and 24P3R, 4 
in primary osteoblasts evaluated by RT-PCR and immunofluorescence, respectively 5 
(Neg.Ctrl=negative control, immunofluorescence performed by omitting the primary antibody). 6 
Data are (A-F) the  mean ± SD or (G-I) representative of three independent experiments. *P<0.05, 7 
**P=0.038 and ***P<0.003 versus OBs-empty (unpaired t-test). 8 
 9 
Figure 6: Effect of LCN2 overexpression on osteoclastogenesis. (A-D) RNA from osteoblasts 10 
transfected with LCN2 (OBs-LCN2) or with the empty vector (OBs-empty) was extracted, retro-11 
transcribed and subjected to comparative real time RT-PCR for (A) RankL, (B) IL-6 and (C) Opg 12 
mRNAs evaluation. Data are normalized versus the housekeeping gene Gapdh. (D) RankL/Opg 13 
ratio. (E) Purified bone marrow mononuclear cells were treated with conditioned media (CM) from 14 
osteoblasts transfected with LCN2 (OBs-LCN2-CM) or with the empty vector (OBs-empty-CM) in 15 
the presence of M-CSF and suboptimal concentrations of RANKL for 7 days. (F) OBs-empty and 16 
OBs-LCN2 cells were co-cultured with purified mouse bone marrow mononuclear cells for 7 days. 17 
(G) Purified bone marrow mononuclear cells were treated with rmLcn2 (100ng/ml). At the end of 18 
the experiment, mature osteoclasts were detected by TRAcP histochemical staining. Results are the 19 
mean ± SD of three independent experiments. *P<0.02 and **P=0.0026 versus OBs-empty; 20 
#P=0.0028 versus OBs-empty-CM; in (F) P=0.06 versus OBs-empty (unpaired t test). 21 
 22 
 23 
Figure 7: LCN2 overexpression in HEK293 cells.  HEK293 cells were transfected with an empty 24 
vector (HEK-empty) or with a construct carrying LCN2 (HEK-LCN2). Cells were collected, the 25 
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RNA was extracted, reverse-transcribed and subjected to comparative real time RT-PCR, using 1 
primer pairs and conditions specific for (A) Lcn2, (B) RankL and (C) Opg. In (D) the Rankl/Opg 2 
ratio was calculated. Results are reported as fold increase and are normalized versus the 3 
housekeeping gene GAPDH. (E) Human peripheral blood mononuclear cells (hPBMCs) obtained 4 
by Ficoll separation were allowed to differentiate into osteoclasts in the presence of M-CSF, 5 
suboptimal concentrations of RANKL and conditioned media from HEK293 cells transfected with 6 
empty vector (HEK-empty-CM) or with LCN2 (HEK-LCN2-CM). (F) hPBMCs, were allowed to 7 
differentiate into osteoclasts as described in (E), with or without osteoprotegerin (OPG). Data are 8 
the mean ± SD of three independent experiments. *P < 0.05 and **P < 0.005 versus HEK-empty; $P 9 
< 0.05 versus HEK-empty-CM and #P< 0.04 versus HEK-empty-CM and HEK-LCN2-CM 10 
(unpaired t test).   11 
 12 
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